[{"id":"66a9f0d8-2474-44d4-a650-49f7ca22de1b","acronym":"RAMO-2","url":"https://clinicaltrials.gov/study/NCT02809053","created_at":"2021-01-18T13:46:41.317Z","updated_at":"2025-02-25T16:24:44.639Z","phase":"Phase 3","brief_title":"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma","source_id_and_acronym":"NCT02809053 - RAMO-2","lead_sponsor":"Archigen Biotech Limited","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • SAIT101 (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 315","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 07/17/2019","primary_completion_date":" 07/17/2019","study_txt":" Completion: 01/10/2020","study_completion_date":" 01/10/2020","last_update_posted":"2020-10-08"}]